

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**漢港控股**  
SINO HARBOUR HOLDINGS

**SINO HARBOUR HOLDINGS GROUP LIMITED**

**漢港控股集團有限公司**

*(Incorporated in Bermuda with limited liability)*

**(Stock Code: 1663)**

**VOLUNTARY ANNOUNCEMENT  
INCORPORATION OF A SUBSIDIARY**

Reference is made to the announcements of Sino Harbour Holdings Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) dated 6 October 2015, 15 December 2015 and 4 November 2016 respectively (the “**Previous Announcements**”) in relation to the entering into by the Company’s wholly-owned subsidiary Sino Harbour Bio Technology Limited (漢港生物科技有限公司) (“**SH BioTech HK**”) of a strategic cooperation framework agreement, a joint venture agreement as well as a supplementary agreement with (i) Irvine Pharmaceutical Services, Inc. (“**IPS**”) and (ii) Zhejiang University of Technology Assets Operation Limited (浙江工業大學資產經營有限公司) (“**Uni Assets Ltd**”). As disclosed in the Previous Announcements, all the relevant parties agreed to incorporate a joint venture company in the People’s Republic of China (the “**PRC**”) to enter into the pharmaceutical inspection industry.

This announcement is made by the Company on a voluntary basis to inform its shareholders and potential investors of the latest information about the Group.

## **INCORPORATION OF A SUBSIDIARY**

The board of directors of the Company (the “**Directors**” and the “**Board**”, respectively) is pleased to announce the incorporation of a new subsidiary of the Company Zhejiang IPS Pharmaceutical Technology Co. Ltd. (浙江美測醫藥科技有限公司) (“**Zhejiang IPS**”), which is jointly held by SH BioTech HK, IPS and Uni Assets Ltd. The shareholdings in Zhejiang IPS held by SH BioTech HK, IPS and Uni Assets Ltd are 75%, 20% and 5% respectively.

Zhejiang IPS was incorporated in the PRC with a registered capital of RMB60.0 million (equivalent to approximately HK\$67.9 million). The business activities of Zhejiang IPS include but are not limited to (i) technology development and consultation; (ii) achievements transfer; and (iii) pharmaceutical and medical devices inspection technology.

## **IMPLICATIONS UNDER THE LISTING RULES**

As all the applicable percentage ratios set out in Rule 14.07 of the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”) in respect of the subscription of the equity interest in Zhejiang IPS by SH BioTech HK (the “**Subscription**”) are less than 5%, the Subscription does not constitute a notifiable transaction of the Company under Chapter 14 of the Listing Rules.

By order of the Board  
**Sino Harbour Holdings Group Limited**  
**SHI Feng**  
*Deputy Chairman and Executive Director*

Hong Kong, 17 February 2017

*As at the date of this announcement, the Board comprises seven Directors, including three executive Directors, namely Mr. SHI Feng (Deputy Chairman and Chief Executive Officer), Mr. WONG Lui and Ms. GAO Lan; one non-executive Director, namely Ms. CHAN Heung Ling (Chairlady); and three independent non-executive Directors, namely Mr. XIE Gang, Mr. LEE Man To and Ms. ZHANG Juan.*